Literature DB >> 28184089

Anticoagulants: Updates on idarucizumab.

J S Chandan, T Thomas, H S Baryah.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28184089     DOI： 10.1038/sj.bdj.2017.95

Source DB:  PubMed          Journal:  Br Dent J        ISSN： 0007-0610            Impact factor:   1.626


× No keyword cloud information.
  7 in total

1.  Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke.

Authors:  Joachim G Schulz; Bernard Kreps
Journal:  J Neurol Sci       Date:  2016-09-09       Impact factor: 3.181

2.  Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.

Authors:  Lene Rosenberg; Gustav Gerstrøm; Mads Nybo
Journal:  Basic Clin Pharmacol Toxicol       Date:  2016-12-16       Impact factor: 4.080

3.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

4.  Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Authors:  David J Graham; Marsha E Reichman; Michael Wernecke; Rongmei Zhang; Mary Ross Southworth; Mark Levenson; Ting-Chang Sheu; Katrina Mott; Margie R Goulding; Monika Houstoun; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman
Journal:  Circulation       Date:  2014-10-30       Impact factor: 29.690

5.  Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

Authors:  Stephan Glund; Joachim Stangier; Michael Schmohl; Dietmar Gansser; Stephen Norris; Joanne van Ryn; Benjamin Lang; Steven Ramael; Viktoria Moschetti; Fredrik Gruenenfelder; Paul Reilly; Jörg Kreuzer
Journal:  Lancet       Date:  2015-06-15       Impact factor: 79.321

Review 6.  Dabigatran (Pradaxa(®)): surgeon's friend or foe?

Authors:  N Syyed; M Ansell; V Sood
Journal:  Br Dent J       Date:  2014-12-05       Impact factor: 1.626

7.  Idarucizumab for dabigatran overdose.

Authors:  Marijke Peetermans; Charles Pollack; Paul Reilly; Laurens Liesenborghs; Marc Jacquemin; Jerrold H Levy; Jeffrey I Weitz; Peter Verhamme
Journal:  Clin Toxicol (Phila)       Date:  2016-05-25       Impact factor: 4.467
  7 in total
  1 in total

1.  Erratum: Updates on idarucizumab.

Authors: 
Journal:  Br Dent J       Date:  2017-02-24       Impact factor: 1.626
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.